Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to observe the efficacy and safety of lenvatinib in preventing
high-risk recurrence of hepatocellular carcinoma patients after liver transplantation.The
cases are from patients with hepatocellular carcinoma who underwent liver transplantation in
the liver surgery department of Shanghai Renji Hospital. Patients enrolled in the study were
randomly allocated in the lenvatinib group (54 patients) and the control group (54 patients)
after stable condition.